Clinical trials: Blood Plasma Therapy
COVID-19, Convalescent Plasma
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19.
- Conditions
- COVID-19, Convalescent Plasma, SARS-CoV-2, Pneumonia
- Trial name
- NCT05077930
- Testing
- Convalescent plasma, Standard of care
- Where
- Brazil
- Volunteers
- 38 people
- Sponsor
- Tânia Portella Costa
Stroke, Acute
Endovascular Treatment in Ischemic Stroke Follow-up Evaluation
Study like register with biomarkers samples for patient experiencing acute ischemic stroke, to assess clinical outcomes and different factors that may affect the clinical outcomes.
- Trial name
- ETIS (NCT03776877)
- Where
- 16 sites in France
- Volunteers
- 4,000 people
- Sponsor
- Hopital Foch
Multiple Myeloma, Multiple Myeloma in Relapse
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
- Trial name
- NCT03266692
- Testing
- ACTR087, SEA-BCMA
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cogent Biosciences, Inc.
Multiple Myeloma
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose.
- Trial name
- iinnovate-3 (NCT05590377)
- Testing
- Modakafusp Alfa, Daratumumab
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Multiple Myeloma
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
There is a great need for treatment options in patients with multiple myeloma (MM) after failure of the lenalidomide/dexamethasone regimen as there is no established standard active therapy for these patients.
- Trial name
- NCT01555281
- Testing
- Nelfinavir, Lenalidomide, Dexamethasone
- Where
- 11 sites in Italy, Switzerland
- Volunteers
- 33 people
- Sponsor
- Swiss Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Fall
Relation Between Psychoactive Drugs Overdosage and Severity of Falls in Elderly People
There are many epidemiological data on the relationship between the number or nature of psychoactive medications used and the risk of falling in elderly, but very little on the relationship between the amount of psychoactive…
- Trial name
- MEDIFALL (NCT05991037)
- Testing
- Blood sampling for psychoactive drugs dosage
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Caen
Multiple Myeloma (MM)
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
- Trial name
- NCT07181239
- Testing
- CM336 Injection, Standard Of Care( SOC)
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Keymed Biosciences Co.Ltd
Multiple Myeloma
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of a consolidation therapy with bortezomib in patients with multiple myeloma aged 61 to 75.
- Trial name
- NCT00416208
- Testing
- Bortezomib
- Where
- 37 sites in Germany
- Volunteers
- 154 people
- Sponsor
- Janssen-Cilag G.m.b.H
Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or…
- Trial name
- NCT07051850
- Testing
- Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Sung-Soo Park
Esophageal Cancer
The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma
Circulating microRNA (circ miRNA) and circulating tumor cell (CTC) levels are hypothesized to be associated with response to chemoradiation in patients undergoing treatment for locally advanced esophageal adenocarcinoma.
- Trial name
- NCT02812680
- Testing
- Blood Draw
- Where
- Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
COVID, Acute Respiratory Distress Syndrome
Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome
Corona virus disease 2019 (COVID-19) has been declared as a Pandemic by the World Health Organization (WHO). According to WHO report on March 31st 2020, globally COVID-19 have infected over 750,000 people and caused over 36,000…
- Trial name
- NCT04380935
- Testing
- Convalescent plasma, Standard of care
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Indonesia
Lymphoma, Large B-Cell, Diffuse
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and…
- Trial name
- NCT06289959
- Testing
- cfDNA
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
High-risk Plasma Cell Neoplasms
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.
- Trial name
- NCT07416682
- Testing
- CAR BCMA-CD70-T cells, fludarabine and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Brain Tumor, Childhood Cancer
Biomarkers of Brain Injury in Children With Brain Tumors
The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors.
- Conditions
- Brain Tumor, Childhood Cancer, Childhood Brain Tumor
- Trial name
- BiomarkCBT (NCT07381959)
- Where
- Sweden
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Rotator Cuff Lesions
The Clinical and Biological Effect of ESWT With Combined PRP Therapy on Rotator Cuff Lesions
Through the investigators previous study of the effect of transient increased cellular permeability after ESWT, combined ESWT and PRP may have better effect on the treatment of rotator cuff lesions.
- Trial name
- NCT05032924
- Testing
- PPR group with ESWT, PPR group without ESWT, HA group with ESWT
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma
Prevention of Left Ventricular Dysfunction During Chemotherapy
The investigators' objective is to assess the efficacy of the combined treatment with enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in patients with hematological malignancies submitted to…
- Conditions
- Acute Myeloid Leukemia, Precursor-cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Neoplasm, Multiple Myeloma
- Trial name
- OVERCOME (NCT01110824)
- Testing
- Enalapril and carvedilol
- Where
- 2 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma, New Diagnosis Tumor
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- KRdvsRd (NCT04096066)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 40 sites in Italy
- Volunteers
- 84 people
- Sponsor
- Fondazione EMN Italy Onlus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.